Recurrent Infection with Herpes Simplex Virus after Marrow Transplantation: Role of the Specific Immune Response and Acyclovir Treatment
- 1 May 1984
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 149 (5) , 750-756
- https://doi.org/10.1093/infdis/149.5.750
Abstract
Herpes simplex virus (HSV) reactivation is common after marrow transplantation, with some patients developing frequent and severe recurrences. Sixty patients were studied to determine both the effect of the specific lymphocyte response to HSV on subsequent recurrences and the effect of acyclovir treatment on restoration of this response. Patients with a positive response after the first HSV recurrence had fewer second recurrences (13 of 28 vs. 18 of 19; P < .01) and at a longer interval when they did recur (42 vs. 27 days; P < .0001). Conversely, patients treated with acyclovir had more frequent second recurrences than did those not treated (18 of 21 vs. 13 of 26; P < .05) and they were at a shorter interval when they did recur (27 vs. 36 days; P = .001). Treated patients also had lower specific lymphocyte responses to HSV. These data confirm the importance of the specific immune response to HSV in the determination of the course of HSV infection after marrow transplant.This publication has 3 references indexed in Scilit:
- Intravenous Acyclovir for the Treatment of Primary Genital HerpesAnnals of Internal Medicine, 1983
- Intravenous Acyclovir to Treat Mucocutaneous Herpes Simplex Virus Infection After Marrow TransplantationAnnals of Internal Medicine, 1982
- Cellular Immune Response in Genital Herpes Simplex Virus InfectionNew England Journal of Medicine, 1978